Education
About Us
Working with TipRanks
Follow Us
Altimmune (GB:0A4C)
:0A4C
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.35Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 0.00%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted the anticipation for the IMPACT Phase 2b NASH trial results and financial strategies to support development. The expansion into AUD and ALD also shows growth potential. However, net losses and R&D expenses remain concerns.Company Guidance
During Altimmune's first quarter 2025 financial results conference call, the company provided optimistic guidance on several fronts. The firm anticipates announcing the results of its IMPACT Phase 2b NASH trial this quarter, with expectations of achieving statistical significance at 24 weeks for both NASH endpoints and clinically meaningful weight loss. The company also revealed a new $100 million credit facility with Hercules Capital, bolstering their financial position to support ongoing and future trials. Altimmune is planning Phase 2 trials for alcohol use disorder (AUD) and alcohol liver disease (ALD) within the second and third quarters of 2025, respectively. The company's cash balance increased to $150 million, supported by a $35 million raise from an ATM facility in the first quarter. Further, they reported a net loss of $19.6 million for the quarter, an improvement from the previous year's $24.4 million. Altimmune's leadership emphasized the potential of their lead candidate, pemvidutide, to be a transformative treatment across multiple fibrotic liver diseases, highlighting the drug's unique profile combining liver fat reduction and weight loss.Upcoming Readout of IMPACT Phase 2b NASH Trial
The trial aims to show statistical significance on NASH endpoints at 24 weeks, a first among incretins, and combines these effects with clinically meaningful weight loss.
Credit Facility with Hercules Capital
Altimmune entered a credit facility for up to $100 million, providing financial flexibility to support the development of pemvidutide.
Successful Enrollment in IMPACT Phase 2b Trial
The trial enrolled 212 participants, exceeding the original target and increasing study power.
Potential Expansion into AUD and ALD
Plans for Phase 2 trials in Alcohol Use Disorder and Alcohol Liver Disease, areas with significant unmet medical needs, were unveiled, potentially expanding pemvidutide's application.
Strong Financial Position
Altimmune ended Q1 2025 with $150 million in cash, cash equivalents, and short-term investments, an increase from $132 million at year-end 2024.
GB:0A4C Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0A4C Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $4.30 | $4.30 | 0.00% |
Feb 27, 2025 | $6.68 | $6.68 | 0.00% |
Nov 12, 2024 | $7.21 | $9.58 | +32.78% |
Aug 08, 2024 | $5.60 | $6.39 | +14.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Altimmune (GB:0A4C) report earnings?
Altimmune (GB:0A4C) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Altimmune (GB:0A4C) earnings time?
Altimmune (GB:0A4C) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Altimmune stock?
The P/E ratio of Altimmune is N/A.
What is GB:0A4C EPS forecast?
GB:0A4C EPS forecast for the fiscal quarter 2025 (Q2) is -0.3.